Research programme: PPAR pan-agonists for obesity - Plexxikon

Alternative Names: Nuclear receptor therapeutic for obesity - Plexxikon

Latest Information Update: 04 Nov 2017

Price : ^*

* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

Originator Plexxikon
Class Small molecules
Mechanism of Action Peroxisome proliferator-activated receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

No development reported Obesity

Most Recent Events

04 Nov 2017 No recent reports of development identified for preclinical development in Obesity in USA
04 Apr 2011 Plexxikon has been acquired by Daiichi Sankyo Company
22 Sep 2010 Preclinical development is ongoing

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.